Recent meaningful negative changes in fundamentals have impacted Medifast Inc. (NYSE: MED): significant quarterly sales deceleration occurred, the consensus estimate for December, 2024 decreased significantly, and the consensus estimate for December, 2025 decreased significantly.
Medifast Inc. (NYSE: MED) suffers from notable negative changes in investment behavior: negative upside/downside volume developed.
In light of these highly negative signals we are reviewing our current Overall Rating of F. We would continue to view the shares with caution pending completion of this review in the next several days.
Current PriceTarget Research Rating
Reflecting future returns on capital that are forecasted to exceed the cost of capital, MED is expected to continue to be a Value Builder.
Medifast has a current Value Trend Rating of F (Lowest Rating). The Value Trend Rating reflects inconsistent signals from PTR’s two proprietary measures of a stock’s attractiveness. Medifast has a neutral Appreciation Score of 54 but a very low Power Rating of 2, producing the Lowest Value Trend Rating.
Recent Price Action
Medifast Inc. (NYSE: MED) stock declined by -2.8% on 2/28/24. The shares closed at $40.57. This decline was accompanied by normal trading volume. Relative to the market the stock has been extremely weak over the last nine months and has declined -17.1% during the last week.
Be the first to comment